Carry On Cosentyx As Novartis Lines Up More Blockbusters
Executive Summary
The Swiss giant has posted a strong set of results with the company highly confident that its flagship immune drug can keep the competition at bay.
You may also be interested in...
FDA Backs Novartis MS Pill Mayzent With Broad Label
Mayzent is the first oral therapy proven to delay progression in patients with secondary progressive multiple sclerosis and Novartis pharma chief Paul Hudson tells Scrip its $88,500 list price will not affect access.
Novartis Can't Halt Janssen's Promo Comparing Their Psoriasis Drugs
US judge is 'troubled' by Janssen's omission of relevant safety data in summary of Tremfya v. Cosentyx study, but finds Novartis claim of irreparable harm is 'too speculative.'
AbbVie's Skyrizi Poised To Enter Packed Psoriasis Market
AbbVie could be looking at near-simultaneous launches for Skyrizi on both sides of the Atlantic after the psoriasis drug – a key future growth driver – got a positive opinion from Europe's regulators some two months before the FDA is due to give its verdict on the interleukin-23 inhibitor.